For instance, incorporating inflammatory markers (e.g., C-reactive protein and interleukin-6) or imaging modalities (e.g., CT-based emphysema quantification) could provide a more comprehensive understanding of disease progression and comorbidities. This evidence concerns the gene CRP and pulmonary emphysema.